D. Waltz

发表

Identification of the urokinase receptor as an adhesion receptor for vitronectin.

S. Rosenberg, Y. Wei, D. Waltz, 1994, The Journal of biological chemistry.

Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006.

Marshall I Hertz, E. Trulock, D. Waltz, 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis

G. Sawicki, D. Waltz, D. Pasta, 2008, Pediatric pulmonology.

Nonproteolytic role for the urokinase receptor in cellular migration in vivo.

S. Zhuo, S. Rosenberg, D. Waltz, 2000, American journal of respiratory cell and molecular biology.

Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Y. Wei, D. Waltz, H. Chapman, 1997, The Journal of clinical investigation.

Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.

J. Pilewski, T. Barto, D. Waltz, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

S. McColley, D. Waltz, E. Rietschel, 2014, The Lancet. Respiratory medicine.

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

L. Lands, D. Waltz, P. Dřevínek, 2019, The New England journal of medicine.

Novel Outcome Measures for Clinical Trials in Cystic Fibrosis

H. Tiddens, D. Waltz, S. Donaldson, 2014, Pediatric pulmonology.

Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Study of Aerosolized Interferon Gamma‐1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease

R. Gibson, I. Noth, P. Anderson, 2005, Pediatric pulmonology.

Randomized , Double-Blind , Placebo-Controlled , Dose-Escalating Study of Aerosolized Interferon Gamma-1 b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease

R. Gibson, I. Noth, P. Anderson, 2005 .

MDCT Evaluation of the Prevalence of Tracheomalacia in Children With Mediastinal Aortic Vascular Anomalies

Edward Y Lee, D. Zurakowski, P. Boiselle, 2008, Journal of thoracic imaging.

MDCT assessment of tracheomalacia in symptomatic infants with mediastinal aortic vascular anomalies: preliminary technical experience

Edward Y Lee, D. Zurakowski, P. Boiselle, 2007, Pediatric Radiology.

Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy.

D. Waltz, H. Chapman, David A. Waltz, 1994, The Journal of biological chemistry.

Role of Urokinase Receptor and Caveolin in Regulation of Integrin Signaling

Y. Wei, D. Waltz, H. Chapman, 1999, Thrombosis and Haemostasis.

American Society of Transplantation Executive Summary on Pediatric Lung Transplantation

D. Waltz, G. Visner, A. Faro, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006.

E. Trulock, D. Waltz, M. Hertz, 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis.

D. Waltz, T. Lahiri, 2001, Pediatrics.

Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.

D. Waltz, H. Chapman, L. Sailor, 1993, The Journal of clinical investigation.

Lack of association of secretory component with IgA in J chain-deficient mice.

J. Seidman, D. Waltz, M. Neutra, 1996, Journal of immunology.

FEV1 as a guide to lung transplant referral in young patients with cystic fibrosis

D. Waltz, W. Robinson, 2000 .

Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.

J. Emerson, R. Gibson, D. Waltz, 2007, Chest.

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

H. Magnussen, H. Watz, D. Waltz, 2013, European Respiratory Journal.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

C. Teneback, P. Sosnay, R. Klingsberg, 2019, The Lancet.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

C. Goss, G. Sawicki, D. Waltz, 2017, The Lancet. Respiratory medicine.

Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.

L. Kalish, D. Goldmann, D. Waltz, 2006, American journal of respiratory and critical care medicine.

FEV(1) as a guide to lung transplant referral in young patients with cystic fibrosis.

D. Waltz, W. Robinson, 2000, Pediatric pulmonology.

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

R. Gibson, T. Reynolds, D. Waltz, 2001, Human gene therapy.

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.

G. Sawicki, S. McColley, C. Owen, 2019, The Lancet. Respiratory medicine.

Hydroxychloroquine and surfactant protein C deficiency.

D. Waltz, Dennis Rosen, 2005, The New England journal of medicine.

Figure 1. Chest Radiographs and a CT Scan in a Boy with Surfactant Protein C Deficiency Treated with Hydroxychloroquine.

D. Waltz, Dennis Rosen, 2005 .

Lumacaftor/Ivacaftor in Patients Aged 6‐11 Years with Cystic Fibrosis and Homozygous for F508del‐CFTR

M. Rosenfeld, D. Waltz, F. Ratjen, 2017, American journal of respiratory and critical care medicine.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

S. Stanojevic, D. Waltz, J. Davies, 2017, The Lancet Respiratory Medicine.

Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis.

A. Ceppe, D. Waltz, S. Donaldson, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

F. van Goor, D. Waltz, E. Tullis, 2018, The New England journal of medicine.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR

S. McColley, D. Waltz, E. Rietschel, 2017, Annals of the American Thoracic Society.

Cutaneovisceral Angiomatosis With Thrombocytopenia

J. Mulliken, A. Perez-Atayde, D. Waltz, 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients

S. M. Robinson, M. Riley, D. Waltz, 2010, Microbiology.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Xiaohong Huang, Michael P Boyle, Carla Colombo, 2015, The New England journal of medicine.

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles

D. Waltz, B. Ramsey, E. Tullis, 2019, ERJ Open Research.

Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.

R. Parad, D. Waltz, H. Dorkin, 2004, Pediatrics.

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2003, American journal of respiratory and critical care medicine.

Tracheomalacia and tracheobronchomalacia in children and adults: an in-depth review.

Armin Ernst, A. Ernst, D. Waltz, 2005, Chest.

Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Thomas Ferkol, Carlos Milla, Frank Accurso, 2007, Human gene therapy.

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

J. Clancy, D. Waltz, B. Ramsey, 2004, Chest.

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.

D. Waltz, J. Elborn, B. Ramsey, 2016, The Lancet. Respiratory medicine.

VX‐659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Prais, F. van Goor, D. Waltz, 2018, The New England journal of medicine.

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

P. Sosnay, F. van Goor, D. Waltz, 2023, The Lancet. Respiratory medicine.

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

R. Gibson, S. McColley, D. Waltz, 2021, American journal of respiratory and critical care medicine.

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.

R. Fischer, S. Mulrennan, D. Waltz, 2021, The Lancet. Respiratory medicine.

Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.

D. Waltz, B. Ramsey, E. Tullis, 2021, The New England journal of medicine.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

S. McColley, D. Waltz, B. Ramsey, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society

N. Segata, F. Armanini, P. Palange, 2018, Italian Journal of Pediatrics.

Highlights of a workshop to discuss targeting inflammation in cystic fibrosis.

S. Randell, E. Gulbins, D. Waltz, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

J. Clancy, D. Renard, H. Danahay, 2013, Chest.

Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis *

D. Waltz, P. Greally, D. Slattery, 2001, Pediatric pulmonology.

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

J. Emerson, R. Gibson, F. Accurso, 2007, Pediatric pulmonology.

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

M. Rosenfeld, D. Waltz, R. Wilmott, 2003, Chest.

Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy.

D. Waltz, G. Marigowda, Fang Liu, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis.

L. Kalish, D. Waltz, C. Gerard, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

WS13.4 Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6–11 years (yrs) with cystic fibrosis (CF) homozygous for F508del-CFTR: a randomized placebo (PBO)-controlled phase 3 trial

S. Stanojevic, D. Waltz, J. Davies, 2017 .

143 Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction

D. Waltz, J. Elborn, B. Ramsey, 2015 .

WS01.3 Lumacaftor in combination with ivacaftor in patients with cystic fibrosis who are homozygous for the F508del-CFTR mutation

D. Waltz, J. Elborn, B. Ramsey, 2015 .

WS7.4 Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: Phase 2 interim analysis

S. Colley, D. Waltz, S. Bell, 2013 .

55 Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-week open-label study

J. Pilewski, T. Barto, D. Waltz, 2017 .

The ISHLT transplant registry: moving forward.

E. Trulock, D. Waltz, M. Hertz, 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Membranous Obliterative Bronchitis: A Proposed Unifying Model

D. Waltz, V. Nosé, A. Colin, 2006, Pediatric pulmonology.

Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial Cystic Transmembrane Regulator Gene Transfer to the Lungs of Patients With Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis

J. Clancy, D. Waltz, B. Ramsey, 2006 .

MDCT Evaluation of the Prevalence of Tracheomalacia in Children With Mediastinal Aortic Vascular Anomalies

Edward Y Lee, D. Zurakowski, P. Boiselle, 2008, Journal of thoracic imaging.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

S. McColley, D. Waltz, J. Davies, 2023, American journal of respiratory and critical care medicine.